Navigation Links
Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions

JACKSONVILLE, Fla., April 14 /PRNewswire-FirstCall/ -- Phlo Corporation (Pink Sheets: PHCP) (the "Company") clarified today that "pre-reverse split" Phlo common stock certificates are negotiable in connection with market transactions and are a valid representation of a holder's current position in Phlo common stock. This clarification was issued in response to information from shareholders that a number of brokers and clearing firms will not negotiate Phlo common stock certificates issued prior to Phlo's 1-for-100 reverse split of its capital stock until such certificates are exchanged for "post-reverse split" certificates.

Although shareholders will receive a request from the Company to surrender their certificates to the transfer agent in exchange for new certificates reflecting the reverse split, this step is NOT required in order to negotiate shares represented by a pre-reverse split certificate. When any pre-reverse split certificate is sent to Phlo's transfer agent for re-registration, the transfer agent automatically re-issues the shares on a post-reverse split basis using certificates bearing the new CUSIP.

Phlo is advised that a number of brokers and clearing firms have submitted all pre-reverse split certificates in their vaults to Phlo's transfer agent in exchange for post-reverse split certificates. However, this step is not required. Shareholders who encounter any difficulty with this process should have their broker contact Phlo directly.

The Company completed its 1-for-100 reverse stock split process on February 5, 2008. On that date, by operation of law and without any action by any person, certificates representing shares of Phlo common stock automatically represented 1/100th of the number of shares set forth on such certificates.

Nasdaq began reflecting the reverse split in the quotation of the price of the Company's common stock in the public market beginning on or about March 19 and assigned the Company's new trading symbol of PHCP. Additionally, the Company acquired a new CUSIP for its post-reverse split certificates. This is largely a "bookkeeping" measure to indicate whether the certificate represents a pre or post reverse split number of shares.

Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.

Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.

SOURCE Phlo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Viragen International to Reverse Split Its Common Stock
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Pharsight Announces 1-For-3 Reverse Stock Split
4. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
5. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
6. PAREXEL International Announces 2-For-1 Stock Split
7. Solar cell directly splits water for hydrogen
8. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Phlo Reverse Stock Split Process Completed; Trading Symbol Changed to PHCP
11. MiMedx Group Announces Post-split Name Change
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):